Dudediligence.

Aytu BioPharma, Inc

AYTUNASDAQ · Pharmaceutical Preparations
Write an idea

Price
FilingsNewest: 10-K, Annual reportSep 22 →InsidersNo open-market buys or sales.→HoldersNantahala 20.3%Stonepine 8.5%AWM Investment 5.8%→Financing →

From the filings

Figures

Revenue
$57.6Mlast 12 months
Net income
−$14.3Mlast 12 months
Operating cash flow
$3.3Mlast 12 months
Cash and equivalents
$26.3Mat the last balance sheet
Total debt
$11.0Mat the last balance sheet
Shares outstanding
10.7M shareson issue
Every year and quarter →